Neoadjuvant Chemotherapy Therapy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Conditions: Neoadjuvent; PD-1 Inhibitor; Chemotherapy; Esophageal Squamous Cell Carcinoma Intervention: Drug: Pembrolizumab, Albumin Paclitaxel, 5-fluorouracil, Cisplatin Sponsor: Tang-Du Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Condition: TNBC - Triple-Negative Breast Cancer Interventions: Drug: Camrelizumab Plus Chemotherapy and Famitinib; Drug: Camrelizumab Plus Chemotherapy Sponsor: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2023 Category: Research Source Type: clinical trials
